IL87692A - Monoclonal anti-idiotypic antibodies which specifically recognize idiotypes present on second antibodies and their production - Google Patents

Monoclonal anti-idiotypic antibodies which specifically recognize idiotypes present on second antibodies and their production

Info

Publication number
IL87692A
IL87692A IL8769288A IL8769288A IL87692A IL 87692 A IL87692 A IL 87692A IL 8769288 A IL8769288 A IL 8769288A IL 8769288 A IL8769288 A IL 8769288A IL 87692 A IL87692 A IL 87692A
Authority
IL
Israel
Prior art keywords
mab
tumor
cells
antibody
antigen
Prior art date
Application number
IL8769288A
Other languages
English (en)
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/116,802 external-priority patent/US4918164A/en
Application filed by Oncogen filed Critical Oncogen
Publication of IL87692A publication Critical patent/IL87692A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5757—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofoetal proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL8769288A 1987-09-10 1988-09-07 Monoclonal anti-idiotypic antibodies which specifically recognize idiotypes present on second antibodies and their production IL87692A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9609587A 1987-09-10 1987-09-10
US07/116,802 US4918164A (en) 1987-09-10 1987-11-04 Tumor immunotherapy using anti-idiotypic antibodies
US07/225,446 US5614610A (en) 1984-12-21 1988-07-28 Tumor immunotherapy using anti-idiotypic antibodies

Publications (1)

Publication Number Publication Date
IL87692A true IL87692A (en) 1994-04-12

Family

ID=27378089

Family Applications (1)

Application Number Title Priority Date Filing Date
IL8769288A IL87692A (en) 1987-09-10 1988-09-07 Monoclonal anti-idiotypic antibodies which specifically recognize idiotypes present on second antibodies and their production

Country Status (16)

Country Link
US (1) US5614610A (fr)
EP (2) EP0306995B1 (fr)
JP (1) JPH02494A (fr)
AT (1) ATE151079T1 (fr)
AU (1) AU630592B2 (fr)
DE (1) DE3855850T2 (fr)
DK (1) DK500888A (fr)
ES (1) ES2102978T3 (fr)
FI (1) FI884114L (fr)
GR (1) GR3023725T3 (fr)
HU (1) HU206394B (fr)
IL (1) IL87692A (fr)
NO (1) NO178464C (fr)
NZ (1) NZ226129A (fr)
OA (1) OA08952A (fr)
PT (1) PT88459B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255209A (ja) * 1984-05-30 1985-12-16 Mitsubishi Heavy Ind Ltd 圧延機におけるエツジヤ開度制御方法
AU607533B2 (en) * 1987-08-07 1991-03-07 Xoma Corporation Methods and compositions for mimicking antigenic determinants
US6432402B1 (en) 1989-05-25 2002-08-13 Sloan-Kettering Institute For Cancer Research Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
EP1334984A1 (fr) * 1989-05-25 2003-08-13 Sloan-Kettering Institute For Cancer Research Anticorps anti-idiotypiques induisant une réaction immunitaire contre un glycosphingolipide, et son utilisation
US6805862B1 (en) 1989-05-25 2004-10-19 Sloan-Kattering Institute For Cancer Research Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
ATE184704T1 (de) * 1989-11-03 1999-10-15 Donald L Morton Nachweismethode für harnkarzinom-assoziierte antigene
JPH04148298A (ja) * 1990-10-08 1992-05-21 Matsushita Electric Ind Co Ltd 違法駐車検出警告装置
DE4208795A1 (de) * 1992-03-19 1993-09-23 Behringwerke Ag Monoklonaler anti-gangliosid-antikoerper, seine herstellung und verwendung als tumortherapeutikum
SE470285B (sv) * 1992-05-22 1994-01-10 Volvo Penta Ab Drivaggregat för fartyg
US5861158A (en) * 1993-11-17 1999-01-19 The United States Of America As Represented By The Deptartment Of Health And Human Services Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US7354587B1 (en) * 1994-07-06 2008-04-08 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
AU5909900A (en) * 1999-07-02 2001-01-22 Life Time Pharmaceuticals, Inc. Predicting immunotherapy effectiveness through delayed type hypersensitivity
EP1221961A4 (fr) * 1999-10-13 2004-03-31 Roswell Park Memorial Inst Induction d'une forte reponse immunitaire a un auto-antigene associe aux tumeurs
CA2515779A1 (fr) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Methodes et compositions contraceptives associees aux interferences des proteasomes
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
DE10352977A1 (de) * 2003-11-13 2005-06-09 Müller-Hermelink, Hans Konrad, Prof. Dr. Muriner anti Idiotyp-Antikörpers oder anti Idiotyp-Antikörper aus der Ratte des humanen monoklonalen SC-1 Antikörpers
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
JP4929864B2 (ja) 2006-06-15 2012-05-09 株式会社デンソー 配管継手装置
CN102186499B (zh) * 2008-08-20 2015-05-20 Ibc医药公司 用于癌症治疗的对接和锁定(dnl)疫苗
AU2011295968B2 (en) * 2010-09-01 2017-01-05 Biogen Ma Inc. Rapid generation of anti-idiotypic antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720884B2 (ja) * 1983-11-07 1995-03-08 ザ・ウイスタ−・インスティテュ−ト 抗イデイオタイプ抗体によって誘発される、腫瘍およびウイルスに対する免疫応答
JPS60155133A (ja) * 1983-11-09 1985-08-15 シンビオテイツクス　コ−ポレイシヨン アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies

Also Published As

Publication number Publication date
EP0759442A1 (fr) 1997-02-26
NO178464C (no) 1996-04-03
JPH02494A (ja) 1990-01-05
AU2207788A (en) 1989-03-16
DE3855850D1 (de) 1997-05-07
EP0306995A3 (fr) 1990-03-07
AU630592B2 (en) 1992-11-05
FI884114A0 (fi) 1988-09-07
NO884024D0 (no) 1988-09-09
DE3855850T2 (de) 1997-11-20
ATE151079T1 (de) 1997-04-15
EP0306995B1 (fr) 1997-04-02
FI884114A7 (fi) 1989-03-11
EP0306995A2 (fr) 1989-03-15
US5614610A (en) 1997-03-25
HUT47973A (en) 1989-04-28
PT88459B (pt) 1993-01-29
DK500888D0 (da) 1988-09-09
OA08952A (fr) 1990-11-30
GR3023725T3 (en) 1997-09-30
HU206394B (en) 1992-10-28
NO178464B (no) 1995-12-27
DK500888A (da) 1989-03-11
NO884024L (no) 1989-03-13
ES2102978T3 (es) 1997-08-16
FI884114L (fi) 1989-03-11
NZ226129A (en) 1991-12-23

Similar Documents

Publication Publication Date Title
US4918164A (en) Tumor immunotherapy using anti-idiotypic antibodies
EP0306995B1 (fr) Immunothérapie pour les tumeurs par utilisation d'anticorps anti-idiotypiques
Vadhan-Raj et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.
US5653977A (en) Anti-idiotypic antibody that mimics the GD2 antigen
Weiner et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII
US5091178A (en) Tumor therapy with biologically active anti-tumor antibodies
Raychaudhuri et al. Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen.
Raychaudhuri et al. Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta).
JPH03502762A (ja) Ｔ細胞抗原レセプターの特定の領域に対して反応性のモノクローナル抗体
US5612030A (en) Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
WO1992016646A1 (fr) Anticorps anti-idiotype contre l'antigene proteoglycane associe aux melanomes humains
Saleh et al. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.
JPH11500607A (ja) マウスモノクローナル抗イディオタイプ抗体３ｈ１
Durrant et al. An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours
Fagerberg et al. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1) I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?
Pohl et al. CD30‐specific AB1‐AB2‐AB3 internal image antibody network: potential use as anti‐idiotype vaccine against Hodgkin's lymphoma
JPH08510460A (ja) モノクローナル抗イディオタイプ抗ｃａ１２５抗体およびこれらを含有する医薬組成物
DeFreitas et al. Human antibody induction to the idiotypic and anti-idiotypic determinants of a monoclonal antibody against a gastrointestinal carcinoma antigen
Lee et al. Idiotypic interactions in immune responses to tumor-associated antigens
EP0234122A2 (fr) Thérapie de tumeur avec des anticorps anti-tumeur biologiquement actifs
CA1339816C (fr) Immunotherapie contre les tumeurs utilisant des anticorps anti-idiotypiques
US5766588A (en) Tumor immunotherapy using anti-idiotypic antibodies
Wekerle et al. Thymus-derived rat lymphocyte receptor for cell surface antigens is a nonserologically defined product of the major histocompatibility gene complex.
Devaux et al. Cross-reactive idiotypes of monoclonal anti-Iak antibodies: characterization with xenogeneic anti-idiotypic reagents and expression in anti-H-2 humoral responses.
Perosa et al. Human CD4-internal antigen anti-idiotypic monoclonal antibody: induction of a CD4-specific response in humans

Legal Events

Date Code Title Description
RH Patent void